DDX53 and cancer: Finally, immunity was further examined using a rechallenge experiment (as shown in the far-right column of Table 4) and revealed that almost all regimens were significantly active in stimulating immunity, thereby effectively inhibiting the rechallenge-induced proliferation of CT26 cancer cells.